View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, Induction, Multiple Myeloma, Cycle 2-4
Protocol-ID: 1719 V1.1 (Mini), BORT1.3/DRTM16/LENA25/DEXA20, Ind., MM, C2-4Indication(s)
- Multiple Myeloma; ICD-10 C90.-, C90.0-
Links
- Daratumumab: Risiko der Reaktivierung von Hepatitis B [BfARM Risikoinf. Rote Hand etc.]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 15.04.2021